Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series
- 536 Downloads
Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive malignancy with poor outcome occurring in adolescents and young adults. Therapeutic options for patients with advanced disease are limited. Preclinical studies have shown that VEGFR-2 and VEGFA are overexpressed in DSRCT and that DSRCT xenografts were highly responsive to anti-VEGF agents such as bevacizumab. We report here the clinical activity of sunitinib in eight patients with DSCRT. Our data suggest that sunitinib may be associated with clinical benefit even in heavily pretreated patients.
KeywordsDesmoplastic round cell tumor Sunitinib Treatment
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Fletcher CDM, Unni KK, Mertens F (eds) (2002) World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, LyonGoogle Scholar
- 5.George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27:3154–3160PubMedCrossRefGoogle Scholar